NSECertificate under SEBI (Depositories and Participants) Regulations, 201810 Jul 2026 · 10 Jul 2026, 11:08 am

Certificate under SEBI (Depositories and Participants) Regulations, 2018

Mankind Pharma Limited · MANKIND

✦ AI SummaryRegulatory

Mankind Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming no dematerialisation/rematerialisation of shares for the quarter ended June 30, 2026.

Analysis Scores

Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk8/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Mankind Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

Attachments (1)

📄

MANKIND1_10072026110849_Covering_letter_74.pdf

pdf

Download →
View document text
July 10, 2026 BSE Limited National Stock Exchange of India Limited P J Towers, Exchange Plaza, C-1, Block G, Dalal Street, Bandra Kurla Complex, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 543904 Symbol: MANKIND Dear Sir/ Madam, Subject: Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 Pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, kindly find enclosed herewith a copy of the certificate received from KFin Technologies Limited, the Registrar and Share Transfer Agent of the Company for the quarter ended on June 30, 2026. Request you to kindly take the above on record. Thanking You, Yours Faithfully, For Mankind Pharma Limited Hitesh Kumar Jain Company Secretary & Compliance Officer Encl.: A/a R:/KFIN/R74(5) Date: 09.07.2026 THE COMPANY SECRETARY MANKIND PHARMA LIMITED 236, OKHLA INDUSTRIAL ESTATE PHASE – 3, NEW DELHI, 110020 Dear Sir(s), Sub: Certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories & Participants) Regulations 2018 ('Regulations') for the quarter ended June 30, 2026. With reference to the above captioned Regulations, we hereby confirm that during the period from April 01, 2026, to June 30, 2026, we have not received any requests for dematerialisation/rematerialisation of shares of Mankind Pharma Limited, as required under Regulation 74(5) of SEBI (Depositories and participants) Regulations 2018. Thanking you, Yours faithfully, KFIN TECHNOLOGIES LIMITED Dnyanesh Gharote Vice President